Cost-Effectiveness of First-Line Regimens for Helicobacter pylori Infection in the United States
BQT was found to be the cost-effective first-line treatment. Rifabutin triple therapy was a cost-effective alternative. Policymakers should prioritize BQT and rifabutin triple therapy versus other therapies.
Authors
- Marjorie V. Neidecker (ORCID: https://orcid.org/0000-0001-9566-4683)
- Kang Wang (ORCID: https://orcid.org/0009-0001-5839-7878)
- Ligang Liu
- Haoran Yang
- Nahata C. Milap
Institutions
- Sun Yat-sen University (CN)
- King's College London (GB)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- The Ohio State University (US)
- Western University of Health Sciences (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.14309/ajg.0000000000003924
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00